{
  "docId": "019de516-01ce-701d-bd9b-acac15fa9fab",
  "docSlug": "a13be9775a99db49a0c5c2ac3ee2ea88",
  "documentTitle": "Oculis | Investor Conference Presentation Deck | 39 slides",
  "authorId": "oculis",
  "authorName": "Oculis",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 37,
  "pageCount": 39,
  "prevPage": 36,
  "nextPage": 38,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de516-01ce-701d-bd9b-acac15fa9fab/37",
  "deckHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab",
  "deckJsonHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab.json",
  "deckAnchorHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab#slide-37",
  "components": [
    {
      "bbox": {
        "h": 0.07,
        "w": 0.75,
        "x": 0.026,
        "y": 0.89
      },
      "kind": "source-note",
      "text": "OCS-01 is based on the OPTIREACH® technology, OCS-02 is a single chain antibody fragment (ScFv) against TNFα and OCS-05 is a SGK-2 activator peptidomimetic small molecule with novel MoA targeting the activation of the trophic factor pathways.\n(1) Geographic Atrophy (GA).\n(2) Diabetic Retinopathy (DR).\n(3) Age-related Macular Degeneration (AMD).\n(4) Retinal Vein Occlusion (RVO).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "16943613-490b-4e42-a4ec-c8508f0c0730",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.71,
        "w": 0.94,
        "x": 0.03,
        "y": 0.139
      },
      "kind": "table",
      "text": "Product Candidate, Investigational Indication(s), Pre-clinical, Phase 1, Phase 2, Phase 3, Catalysts 2023, Catalysts 2024",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f9551108-a032-498d-b301-0f436c802576",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.84,
        "x": 0.026,
        "y": 0.045
      },
      "kind": "title",
      "text": "Multi-asset, Late-stage Pipeline & Near-term Catalysts Expected",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "354e2969-c07f-4f7f-9c21-007003fcf258",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "NxN matrix",
      "slug": "matrix-nxn",
      "agent": null,
      "layer": "slide",
      "matchId": "a73a25a5-b5a4-45f4-9f74-88a927afa07a",
      "evidence": "table/data: Product Candidate, Investigational Indication(s), Pre-clinical, Phase 1, Phase 2, Phase 3, Catalysts 2023, Catalysts 2024",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 39,
      "from": 25,
      "beatId": "6cce666b-f795-4a3e-a589-afe2a7266ece",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "Slides 25-39 discuss OCS-02, OCS-05, and the track record of efficient capital deployment.",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}